about
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinTargeting gastrointestinal stromal tumors: the role of regorafenibDermatofibrosarcoma protuberans: from translocation to targeted therapyEpithelioid Sarcoma: Opportunities for Biology-Driven Targeted TherapyEfficacy and safety of eribulin mesylate in advanced soft tissue sarcomasTreatment of soft tissue sarcoma: a focus on earlier stages.Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.The evolution of systemic therapy in sarcoma.Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics.Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.Advanced aggressive fibromatosis: Effective palliation with chemotherapy.Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants.Synovial sarcoma diagnosis and management in the era of targeted therapies.Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies.A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Dear John Hunter.A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas.Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the GallbladderThe spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities.Phase III Soft Tissue Sarcoma Trials: Success or Failure?Cardio-oncology: an ongoing evolution.Current and advancing systemic treatment options for soft tissue sarcomas.Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcomaThe effect of surgery with radiation on pelvic Ewing sarcoma survival.Olaratumab for the treatment of soft-tissue sarcoma.Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies.Epithelioid Sarcoma: Diagnostic Features and Genetics.Phosphoproteomics in translational research: a sarcoma perspective.Eribulin in advanced liposarcoma and leiomyosarcoma.Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.Novel therapeutic approaches in chondrosarcoma.PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.
P50
Q26738346-C1DA5AB4-A9BD-4B1B-80D4-A8E308CD1EC6Q26747162-4717B66C-E152-4C97-8413-C62FF7FF2F5BQ26771387-6F03B3B2-010C-4137-9F92-1BB24D2D8F87Q26782730-6493E231-F168-4914-BC29-C58CC79404D4Q28078116-607AC978-1737-42EA-BCEF-B44108D2DE16Q30240235-0E5AA8CE-53C6-4EE8-8BBD-9D6A002978F2Q30245586-C1687104-D7D1-474C-8A66-49EB01D04808Q30491565-0B5EB120-B25A-4441-89AA-EF227F94E40FQ33274710-33E2F10C-5BE4-4F9A-B782-B91D98E63F3EQ33276384-98955AC7-D6C9-40AB-9D97-009BA96AFEB7Q33843830-386FE0F4-4808-4326-A413-7C0E2EEECA17Q34045975-B8043DE7-C9C2-44BC-93B4-6B072009643AQ34046989-5D10AFC6-CF14-42AA-9BBC-207EEC63C714Q34612012-89FA682E-3CB7-48E7-807A-F26C78819B03Q34622925-E433990F-2E07-49A8-813E-B01387E457E3Q34651237-B630BE86-085D-43AF-97B1-D50707B81E3AQ34670431-6D5F5BCE-C698-4CE6-A05E-FBD2DC9EA928Q34679524-6012C257-28C0-420D-A2F9-D25277193E74Q35616803-5497C46C-37BF-44F6-800E-268DEED3D9D5Q36224107-5E6D9A3E-C338-4230-B620-B6B0B140AD9DQ37043932-78C8563F-403A-45AB-A5C9-1D3D26154FC7Q37350801-E4A5A8B5-3BC3-4CD9-80B1-724418DE39CAQ37402813-39EB6B22-70A5-48D6-B3F6-D9AD2B6EAFD3Q37579721-3E550A53-0290-4126-A8B2-9E84BBDBB6A3Q37691485-5ADE557A-D6A6-4F87-9D97-F35233A1423BQ37716872-D541AE89-86AF-495D-9599-5F1F9D49BF22Q38551766-B357A68F-3B03-4ADD-988A-D48DC646ACA9Q38563242-5491C566-DCDC-42FD-92CE-8E461627A890Q38591828-83A6900C-1030-4FDE-8B56-274264055524Q38602635-8B2EEA1D-B411-4C19-A5A1-3D29624D8728Q38622682-69DCD2DD-42E9-41FA-AA7C-68F35C41AD65Q38651664-7BB776CD-93C5-4BE9-94D5-870914DF99F3Q38662094-6CCE45D4-6563-4B2D-A498-C85FB74DCB0CQ38662097-13EC7588-4E08-4A1D-ACEB-631EC81758B1Q38708614-656EAF92-A2AA-460C-9D64-FB8AB853C24EQ38722807-A4E58766-76C6-4F91-B360-C632D5D88263Q38731757-B77D3BCD-3B22-4C79-A490-0A006A7FDD17Q38764510-89DFCE0A-FEEE-41AA-B291-0F3A3BDD8A2CQ38821916-40F41897-8D03-42A5-9F45-A08B891FBA44Q38823874-9254E4F4-6CDB-4E55-84A2-670AB17D8D2E
P50
description
investigador
@es
researcher
@en
name
Robin L Jones
@en
type
label
Robin L Jones
@en
prefLabel
Robin L Jones
@en
P31
P496
0000-0003-4173-3844